ATS View
한국어

ST Pharm KRX:237690KOSDAQ

에스티팜 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h10
Articles, 7 days32
DART filings, 7 days1
Articles tracked32since Sep 11

In Q2 2026, ST Pharm reported revenue of ₩108bn, up 58.9% year on year, and operating profit of ₩18.3bn. ST Pharm (에스티팜) appeared in 32 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 14 with 30 articles. The most common catalyst was earnings (1). It was most often mentioned alongside Hanmi Pharm.

ST Pharm quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩108bn+58.9%₩18.3bn₩13.2bn
Q1 2026₩67.0bn+27.7%₩11.5bn₩15.2bn
Q4 2025 derived₩129bn+11.5%₩26.3bn₩31.0bn
Q3 2025₩81.9bn+32.7%₩14.7bn₩17.5bn
Q2 2025₩68.3bn+53.1%₩12.9bn₩5.4bn
Q1 2025₩52.4bn+1.4%₩1.0bn₩709m
Q4 2024 derived₩116bn-4.1%₩22.8bn₩12.4bn
Q3 2024₩61.7bn+10.3%₩6.1bn₩13.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

ST Pharm top stories 2 weeks, by number of outlets

  1. 1
    에스티팜, 세계 RNA 석학 한자리에…‘RISC 2026’ 성료
    8 outlets · 8 articlesFirst report Sep 14 09:27 바이오타임즈
  2. 2
    에스티팜, RNA 국제 심포지엄 ‘RISC 2026’ 개최
    7 outlets · 7 articlesFirst report Sep 14 09:16 FETV
  3. 3
    에스티팜, 'RISC 2026'서 RNA 치료제 산업화 전략 논의
    2 outlets · 2 articlesFirst report Sep 14 09:24 메디파나뉴스
  4. 4
    [에스티팜] 세계적 RNA 석학과 함께한 ‘RISC 2026’ 성료
    1 outlets · 1 articlesFirst report Sep 14 09:55 뉴스더보이스헬스케어
  5. 5
    에스티팜, 글로벌 RNA 전문가 한자리에…차세대 전달기술 조명
    1 outlets · 1 articlesFirst report Sep 14 09:55 메디코파마
  6. 6
    에스티팜, RNA 세계적 과학자·산업계 리더 한자리에
    1 outlets · 1 articlesFirst report Sep 14 10:17 의학신문(보사)

Latest ST Pharm news Korean headlines